Drug Company Name:Incepta Pharmaceuticals Ltd. Product List. Serial. No. Brand Name. Dosage. Generic Name. Pack Size. 1. Aboxitin 1 gm. Injection. Incepta has been launching new and innovative products in order to fulfill .. required to attain it would be in their top priority list- They need to. Since its inception, Incepta has been launching new and innovative products in order to fulfill unmet demand .. Following are a few of this long list of products.
|Published (Last):||15 April 2017|
|PDF File Size:||19.18 Mb|
|ePub File Size:||6.43 Mb|
|Price:||Free* [*Free Regsitration Required]|
Select Brand Name Generic Name.
Please Sign Up Here. The company has a very big manufacturing facility located at Savar, 35 kilometer away from the center of the capital city Dhaka. The company produces various types of dosage forms which include tablets, capsules, oral liquids, ampoules, dry powder vials, powder for suspension, nasal sprays, eye drops, creams, ointments, lotions, gels, prefilled syringes, liquid filled hard gelatin capsules, lyophilized injections etc.
Since its inception, Incepta has been launching new and innovative products in order to fulfill unmet demand of the medical community. The focus has always been to bring new, more technologically advanced molecules and innovative dosage forms to this country. Incepta wants to become a research based global pharmaceutical company in addition to being a highly efficient generic manufacturer. To discover and develop innovative, value-added products that improve the quality of life of people around the world.
And contribute towards the growth of our Nation. Provide people globally with high quality health care products at affordable prices in order to improve access to medicine and to provide employees an enabling environment that facilitates realization of their full potential.
Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. Established in the yearthe company has come a long way. Currently the Zirabo plant consists of several buildings with state of the art technology.
Dedicated cephalosporin manufacturing building, a specialized manufacturing building for the production of lyophilized products, insulin and amino acids and newly built liquid and semisolid manufacturing building and large warehouse is also in operation.
Currently all the products are coming from the plant at Zirabo.
The company jncepta produces almost all types of dosage forms covering nearly all therapeutic area. Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 18 different locations throughout the country.
A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. Llst highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product. December 16ththe construction of the factory began. Augustoffice operations began.
Incepta Pharmaceuticals Ltd.
Decemberfirst batch of product Neodin S Ranitidine mg tablet was produced. Januarysales began formally. Februarytraining of the first batch of medical representatives began. Aprilwith the launching of Osartil Losartan Potassium the inceptaa prescription product of Incepta was launched in the market. The company started off in a new direction. A total of 23 new generics with 35 presentations were launched this year.
By the end of Incepta was the number 31st company of the country. In ,There was massive restructuring throughout the company. In ,A total of 18 new generics with 37 presentations were launched this year. By the end of infepta yearIncepta was ranked the 12th company of the country. In ,A total of 32 new generics with 49 presentations were launched. In ,Massive expansion project of the factory was envisioned. New office for the sales and distribution operation was also taking shape.
In ,The company registered an excellent growth of By the end of the year Incepta was ranked the 10th company of the country IMS.
In ,Incepta kept on introducing innovative and newer molecules to the local market. A total of 32 new generics with 48 presentations were launched. In ,The new office Dhanmondi for the sales and distribution operation was inaugurated.
By the end of the yearIncepta was ranked the 8th company of the country IMS. InA total of 17 new generics with 32 presentations have been launched.
In ,The company maintained an excellent growth of InThe ranking went up again and the company was ranked the 5th largest company of the country with the highest growth rate among the top five IMS.
InIncepta thrived under challenge and excelled in venturing into unexplored grounds and continued to satisfy our customers. InA total of 27 new generics with 76 presentations were launched. InThe company maintained an excellent growth of InThe company was ranked 3rd largest with the highest growth among the top five IMS. By Incepta had positioned itself as an innovative research oriented and knowledge based pharmaceutical company specializing in analysis, design and development of new products.
Incepta successfully started overseas marketing operation from May InA total of 25 new generics with 82 presentations were launched.
InThe company maintained the ranking of 3rd largest IMS. InIncepta pioneered the introduction of biotech products Human Insulin and lyophilized products Pantoprazole injection in the Bangladesh pharmaceutical market.
This was the first time a local pharmaceutical company produced such highly sophisticated technology product in the country. InA total of 32 new generics with 82 presentations were launched. Marketing, Sales, Distribution and Administration departments shifted to the fully owned new office premises in Tejgaon, Dhaka.
The international standard head office of Incepta started operation in the new office premises on 1st October, InA marketing and sales team was setup in Myanmar headed by a country manager from the Marketing Strategy Team to promote the 35 products registered with the Myanmar FDA. Continued investment in our core strength that is our manufacturing plant led to recognition from European authorities and on January 11, Incepta attained European “Certificate of GMP Compliance”.
In40 new products with 86 presentations were introduced of which 10 were first ever in Bangladesh. In significant number of products got registration in different countries.
Incepta started venturing in the field of human vaccines and hormonal products. Incepta launched 51 new products in Incepta launched 56 product presentations. Incepta maintained the 2nd largest IMS position in Bangladesh pharmaceutical market in The company showed the strongest growth among the top 10 companies with a growth rate of Incepta is set to prodhct Human Vaccines to the market and become the first Bangladeshi vaccine manufacturing company.
Export has emerged as a focus area for Incepta. With over three hundred products registered in different countries rpoduct is now set to play more important role in the growth of the company. Currently the company exports to 33 countries of the world with many more in the pipeline. Up to June the company has launched 30 products, 7 rpoduct which are first ever in Bangladesh market.
The responsibilities for the technical aspects of Quality Assurance are defined in the Quality Manual. It encompasses all activities necessary to generate, maintain and verify the quality of drugs.
The Head of Quality Assurance or his delegates are responsible for releasing drug substances, excipients, dosage forms and packaging materials. Performances of routine GMP checks are done as per need. Quality Surveillance is responsible for the implementation of the Quality Management System in different areas in collaboration with different departments.
Quality Surveillance play active role in conducting external and internal audits with their follow-ups. The Quality Manual describes how testing instructions are established and used. The testing instructions include the specifications and testing methods. The testing instructions are binding for release testing and for follow-up stability testing. A routine inspection is being done in the name of “Self Inspection” mainly concerned with safety, sanitation and infra-structural facilities leading to GMP including documentation.
Supply of raw materials are mainly obtained from approved suppliers. We select and evaluate the supplier as per procedures. This procedure is also applicable in case of supply of Primary and Secondary Packaging Materials. The second site is currently under development and several projects of finished formulation unit are being set up. The Zirabo manufacturing plant is located about 35 Km north of Dhaka City and covers an area of land about 15, m2. The total built up production area is aboutsquare feet.
Currently the plant consists of a general purpose manufacturing building, a dedicated cephalosporin manufacturing building, and a specialized manufacturing building for the production of lyophilized products, insulin and amino acids in addition to several floors dedicated to the production of solid dosage forms- tablets and capsules.
Final Report Incepta Pharmaceuticals Ltd | Nobo Ahmed –
A newly built liquid and semisolid manufacturing building is also in operation at this site. The site also houses a warehouse for raw, packaging and finished goods. To meet the increasing demand from domestic as well as overseas markets, another warehouse is currently under construction with three times the capacity of the existing one.
At present all the proudct are coming from this plant at Zirabo. Manufacturing and packaging operations are carried out indepta to the validated methods through systematically qualified machines with full documentation at all stages of operations.
The production sites follow the cGMP guidelines for environmental requirements of the manufacturing and packaging area, as well as comply with the EHS requirements.
Temperature and moisture level are maintained at the desired level through this system. Design of the incelta and air-conditioning systems ensure: Prevention of contamination of the product. Protection of the environment.